Clinical trial
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic…
NCT00268411 · GERCOR - Multidisciplinary Oncology Cooperative Group, Other · Unknown status
Key facts
| NCT number | NCT00268411 |
|---|---|
| Title | Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX] |
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, oxaliplatin |
| Enrollment | 80 |
| Start date | Sep 1, 2004 |
| First posted | Dec 22, 2005 |
| Last update posted | May 27, 2008 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: